Jacobs Levy Equity Management Inc. Trims Position in iTeos Therapeutics, Inc. (NASDAQ:ITOS)

Jacobs Levy Equity Management Inc. trimmed its holdings in iTeos Therapeutics, Inc. (NASDAQ:ITOS) by 5.6% in the first quarter, according to its most recent disclosure with the SEC. The fund owned 504,545 shares of the company’s stock after selling 30,116 shares during the period. Jacobs Levy Equity Management Inc. owned 1.40% of iTeos Therapeutics worth $6,882,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also made changes to their positions in the company. Acadian Asset Management LLC purchased a new stake in shares of iTeos Therapeutics in the first quarter valued at about $3,337,000. Jump Financial LLC purchased a new position in iTeos Therapeutics during the fourth quarter worth about $636,000. Federated Hermes Inc. increased its holdings in iTeos Therapeutics by 4,648.4% in the fourth quarter. Federated Hermes Inc. now owns 2,944 shares of the company’s stock valued at $32,000 after buying an additional 2,882 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in iTeos Therapeutics by 53.3% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 8,826 shares of the company’s stock valued at $97,000 after buying an additional 3,069 shares in the last quarter. Finally, Vontobel Holding Ltd. increased its holdings in iTeos Therapeutics by 41.9% in the fourth quarter. Vontobel Holding Ltd. now owns 220,056 shares of the company’s stock valued at $2,410,000 after buying an additional 64,981 shares in the last quarter. 97.16% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of brokerages have issued reports on ITOS. HC Wainwright increased their target price on shares of iTeos Therapeutics from $44.00 to $46.00 and gave the company a “buy” rating in a report on Monday, May 13th. Wedbush reaffirmed an “outperform” rating and issued a $21.00 target price on shares of iTeos Therapeutics in a report on Monday, June 17th.

iTeos Therapeutics Stock Up 0.7 %

Shares of ITOS stock traded up $0.13 during trading hours on Tuesday, hitting $17.47. The company’s stock had a trading volume of 230,961 shares, compared to its average volume of 349,984. The business has a fifty day moving average of $16.15 and a 200-day moving average of $13.24. iTeos Therapeutics, Inc. has a twelve month low of $8.20 and a twelve month high of $18.75.

iTeos Therapeutics (NASDAQ:ITOS) last released its quarterly earnings results on Friday, May 10th. The company reported ($1.07) EPS for the quarter, missing the consensus estimate of ($1.02) by ($0.05). Equities analysts expect that iTeos Therapeutics, Inc. will post -4.57 earnings per share for the current fiscal year.

iTeos Therapeutics Company Profile

Iteos Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients with cancer. The company's lead antibody product candidate, belrestotug, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells, natural killer cells, and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity.